Alberto Casellas - 17 Feb 2026 Form 4 Insider Report for Synchrony Financial (SYF)

Role
EVP, CEO--Health & Wellness
Signature
/s/ Danielle Do as attorney in fact
Issuer symbol
SYF
Transactions as of
17 Feb 2026
Net transactions value
-$2,717,114
Form type
4
Filing time
19 Feb 2026, 16:04:52 UTC
Previous filing
23 Jan 2026
Next filing
03 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Casellas Alberto EVP, CEO--Health & Wellness 777 LONG RIDGE ROAD, C/O CORPORATE SECRETARY, STAMFORD /s/ Danielle Do as attorney in fact 19 Feb 2026 0001763554

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SYF Dividend Equivalent Unit Award $15,040 +208 +0.22% $72.31 93,058 17 Feb 2026 Direct F1
transaction SYF Common Stock Options Exercise $198,734 +5,794 +6.2% $34.30 98,852 17 Feb 2026 Direct F2
transaction SYF Common Stock Sale $2,930,888 -41,514 -42% $70.60 57,338 17 Feb 2026 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYF Phantom Stock Units Award $0 +1 +0.41% $0.000000 185 17 Feb 2026 Common Stock 1 Direct F3
transaction SYF Employee Stock Option (right to buy) Options Exercise $0 -5,794 -50% $0.000000 5,794 17 Feb 2026 Common Stock 5,794 $34.30 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents dividend equivalent units accrued on February 17, 2026 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock.
F2 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 27, 2025.
F3 The reported phantom stock units were acquired pursuant to a dividend reinvestment feature under the Synchrony Financial Deferred Compensation Plan (the "Deferred Compensation Plan") and are to be settled, in cash, six months following the Reporting Person's separation from service to the Company, subject to the requirements set forth in the Deferred Compensation Plan. Each phantom stock unit is the economic equivalent of one share of Synchrony Financial common stock.
F4 The reporting person was awarded 11,588 employee stock options on April 1, 2017, which vested in five equal annual installments of 20% each, beginning on the first anniversary of the grant date.

Remarks:

EVP, CEO--Health & Wellness